- Home
- RCS vs XOMA Comparison
RCS vs XOMA Comparison
Compare RCS & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | XOMA |
|---|---|---|
| Founded | 1994 | 1981 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 308.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCS | XOMA |
|---|---|---|
| Price | $5.72 | $24.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $63.25 |
| AVG Volume (30 Days) | 191.0K | ★ 412.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $77.29 |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $18.40 |
| 52 Week High | $8.00 | $39.92 |
Technical Indicators
Market Signals| Indicator | RCS | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 44.43 |
| Support Level | $5.72 | $22.29 |
| Resistance Level | $6.03 | $27.87 |
| Average True Range (ATR) | 0.13 | 1.41 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 12.12 | 40.14 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.